Advertisement

Phase III trials in ovarian cancer: The evolving landscape of front line therapy

Published:February 12, 2019DOI:https://doi.org/10.1016/j.ygyno.2019.02.008

      Highlights

      • There are many trials underway with biologic agents in combination and after primary chemotherapy for ovarian cancer.
      • SOLO 1 has changed the standard primary therapy for women with BRCA mutated ovarian cancer.
      • Other trials are likely to change the standard of care for the primary treatment of ovarian cancer.

      Abstract

      Introduction

      Ovarian cancer has a high mortality to case ratio. To improve the initial response to therapy, trials of biologic agents in combination with primary chemotherapy and as maintenance after completing chemotherapy are being conducted. Multiple trials are ongoing and this strategy has great promise. However, the changing landscape of primary treatment will make designing future trials in ovarian cancer difficult as there may not be a consensus on the optimal primary therapy.

      Materials and methods

      We reviewed clinicaltrials.gov for recent and ongoing phase III clinical trials that are likely to impact primary therapy in ovarian cancer. We summarized the objectives and the available data from these trials.

      Results

      A total of 12 potentially practice-changing, randomized phase III trials in front line ovarian cancer were identified in which a biologic therapy was added to primary chemotherapy and/or was used in the maintenance setting. These trials included PARP inhibitors (PARPi), anti-angiogenic agents, immuno-oncology agents, and combinations of these agents. Of the 12 trials, 10 are ongoing, one was terminated for futility, and one has been recently reported. All of these trials emphasize the use of maintenance targeted therapy. In addition, 7 randomized phase III trials utilizing hyperthermic intraperitoneal chemotherapy (HIPEC) were identified in the setting of upfront ovarian cancer treatment.

      Discussion

      There are multiple ongoing trials in primary ovarian cancer. These trials investigate PARPi, anti-angiogenic agents, immuno-oncology agents, combinations of these agents, and HIPEC. Many of these trials will mature within the next several years and are likely to change the primary treatment of women with ovarian cancer.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2018.
        CA Cancer J. Clin. 2018; 68: 7-30
        • Miller K.D.
        • Siegel R.L.
        • Lin C.C.
        • Mariotto A.B.
        • Kramer J.L.
        • Rowland J.H.
        • Stein K.D.
        • Alteri R.
        • Jemal A.
        Cancer treatment and survivorship statistics, 2016.
        CA Cancer J. Clin. 2016; 66: 271-289
        • McGuire W.P.
        • Hoskins W.J.
        • Brady M.F.
        • Kucera P.R.
        • Partridge E.E.
        • Look K.Y.
        • Clarke-Pearson D.L.
        • Davidson M.
        Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group).
        Semin. Oncol. 1996; 23: 40-47
        • Ozols R.F.
        • Bundy B.N.
        • Greer B.E.
        • Fowler J.M.
        • Clarke-Pearson D.
        • Burger R.A.
        • Mannel R.S.
        • DeGeest K.
        • Hartenbach E.M.
        • Baergen R.
        • Gynecologic Oncology G.
        Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
        J. Clin. Oncol. 2003; 21: 3194-3200
        • Markman M.
        • Liu P.Y.
        • Wilczynski S.
        • Monk B.
        • Copeland L.J.
        • Alvarez R.D.
        • Jiang C.
        • Alberts D.
        • Southwest Oncology G.
        • Gynecologic Oncology G.
        Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial.
        J. Clin. Oncol. 2003; 21: 2460-2465
        • Bookman M.A.
        • Brady M.F.
        • McGuire W.P.
        • Harper P.G.
        • Alberts D.S.
        • Friedlander M.
        • Colombo N.
        • Fowler J.M.
        • Argenta P.A.
        • De Geest K.
        • Mutch D.G.
        • Burger R.A.
        • Swart A.M.
        • Trimble E.L.
        • Accario-Winslow C.
        • Roth L.M.
        Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.
        J. Clin. Oncol. 2009; 27: 1419-1425
        • Armstrong D.K.
        • Bundy B.
        • Wenzel L.
        • Huang H.Q.
        • Baergen R.
        • Lele S.
        • Copeland L.J.
        • Walker J.L.
        • Burger R.A.
        • Gynecologic Oncology G
        Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
        N. Engl. J. Med. 2006; 354: 34-43
        • Katsumata N.
        • Yasuda M.
        • Takahashi F.
        • Isonishi S.
        • Jobo T.
        • Aoki D.
        • Tsuda H.
        • Sugiyama T.
        • Kodama S.
        • Kimura E.
        • Ochiai K.
        • Noda K.
        • Japanese Gynecologic Oncology G.
        Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.
        Lancet. 2009; 374: 1331-1338
        • Chan J.K.
        • Brady M.F.
        • Monk B.J.
        Weekly vs. Every-3-week paclitaxel for ovarian cancer.
        N. Engl. J. Med. 2016; 374: 2603-2604
        • Walker J.L.
        Intraperitoneal chemotherapy for ovarian cancer.
        Gynecol. Oncol. 2016; 142: 1-2
        • Burger R.A.
        • Brady M.F.
        • Bookman M.A.
        • Fleming G.F.
        • Monk B.J.
        • Huang H.
        • Mannel R.S.
        • Homesley H.D.
        • Fowler J.
        • Greer B.E.
        • Boente M.
        • Birrer M.J.
        • Liang S.X.
        • Gynecologic Oncology G
        Incorporation of bevacizumab in the primary treatment of ovarian cancer.
        N. Engl. J. Med. 2011; 365: 2473-2483
        • Perren T.J.
        • Swart A.M.
        • Pfisterer J.
        • Ledermann J.A.
        • Pujade-Lauraine E.
        • Kristensen G.
        • Carey M.S.
        • Beale P.
        • Cervantes A.
        • Kurzeder C.
        • du Bois A.
        • Sehouli J.
        • Kimmig R.
        • Stahle A.
        • Collinson F.
        • Essapen S.
        • Gourley C.
        • Lortholary A.
        • Selle F.
        • Mirza M.R.
        • Leminen A.
        • Plante M.
        • Stark D.
        • Qian W.
        • Parmar M.K.
        • Oza A.M.
        • Investigators I.
        A phase 3 trial of bevacizumab in ovarian cancer.
        N. Engl. J. Med. 2011; 365: 2484-2496
        • FDA
        AVASTIN (bevacizumab) injection, for intravenous use.
        in: Initial U.S. Approval: 2004. 2018 (In)
      1. FDA Approves Bevacizumab in Combination with Chemotherapy for Ovarian Cancer. FDA, 2018
        • Oza A.M.
        • Cook A.D.
        • Pfisterer J.
        • Embleton A.
        • Ledermann J.A.
        • Pujade-Lauraine E.
        • Kristensen G.
        • Carey M.S.
        • Beale P.
        • Cervantes A.
        • Park-Simon T.W.
        • Rustin G.
        • Joly F.
        • Mirza M.R.
        • Plante M.
        • Quinn M.
        • Poveda A.
        • Jayson G.C.
        • Stark D.
        • Swart A.M.
        • Farrelly L.
        • Kaplan R.
        • Parmar M.K.
        • Perren T.J.
        • investigators It
        Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall suvival results of a phase 3 randomised trial.
        Lancet Oncol. 2015; 16: 928-936
        • Burger R.A.
        • Enserro D.
        • Tewari K.S.
        • Brady M.F.
        • Bookman M.A.
        • Fleming G.F.
        • Huang Q.
        • Homesley H.D.
        • Fowler J.
        • Boente M.
        • Randall L.M.
        • Chan J.K.
        • Ferris J.S.
        • D'iSaia P.J.
        • Copeland L.J.
        • Mannel R.S.
        • Birrer M.J.
        • Monk B.J.
        Final overall survival (OS) analysis of an international randomized trial evaluating bevacizumab (BEV) in the primary treatment of advanced ovarian cancer: A NRG oncology/Gynecologic Oncology Group (GOG) study.
        J. Clin. Oncol. 2018; (abstr 5517)
        • NIH
        Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer (BOOST).
        2017
        • FDA
        LYNPARZA® (Olaparib) Tablets, for Oral Use.
        2018
        • FDA
        FDA Grants Accelerated Approval to new Treatment for Advanced Ovarian Cancer.
        2016
        • FDA
        FDA Approves Rucaparib for Maintenance Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
        2018
        • FDA
        FDA Approves Maintenance Treatment for Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancers.
        2017
        • Moore K.
        • Colombo N.
        • Scambia G.
        • Kim B.G.
        • Oaknin A.
        • Friedlander M.
        • Lisyanskaya A.
        • Floquet A.
        • Leary A.
        • Sonke G.S.
        • Gourley C.
        • Banerjee S.
        • Oza A.
        • Gonzalez-Martin A.
        • Aghajanian C.
        • Bradley W.
        • Mathews C.
        • Liu J.
        • Lowe E.S.
        • Bloomfield R.
        • DiSilvestro P.
        Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer.
        N. Engl. J. Med. 2018; 379: 2495-2505https://doi.org/10.1056/NEJMoa1810858
        • FDA
        FDA Approves Olaparib for First-line Maintenance of BRCA-mutated Advanced Ovarian Cancer.
        2018
        • Nishio S.
        • Takekuma M.
        • Takeuchi S.
        • Kawano K.
        • Tsuda N.
        • Tasaki K.
        • Takahashi N.
        • Abe M.
        • Tanaka A.
        • Nagasawa T.
        • Shoji T.
        • Xiong H.
        • Nuthalapati S.
        • Leahy T.
        • Hashiba H.
        • Kiriyama T.
        • Komarnitsky P.
        • Hirashima Y.
        • Ushijima K.
        Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer.
        Cancer Sci. 2017; 108: 2213-2220
        • NIH
        Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
        2015
        • NIH
        A Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy.
        2018
        • Hamanishi J.
        • Mandai M.
        • Ikeda T.
        • Minami M.
        • Kawaguchi A.
        • Murayama T.
        • Kanai M.
        • Mori Y.
        • Matsumoto S.
        • Chikuma S.
        • Matsumura N.
        • Abiko K.
        • Baba T.
        • Yamaguchi K.
        • Ueda A.
        • Hosoe Y.
        • Morita S.
        • Yokode M.
        • Shimizu A.
        • Honjo T.
        • Konishi I.
        Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer.
        J. Clin. Oncol. 2015; 33: 4015-4022
        • Wieser V.
        • Gaugg I.
        • Fleischer M.
        • Shivalingaiah G.
        • Wenzel S.
        • Sprung S.
        • Lax S.F.
        • Zeimet A.G.
        • Fiegl H.
        • Marth C.
        BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer.
        Oncotarget. 2018; 9: 17501-17511
        • Zehir A.
        • Benayed R.
        • Shah R.H.
        • Syed A.
        • Middha S.
        • Kim H.R.
        • Srinivasan P.
        • Gao J.
        • Chakravarty D.
        • Devlin S.M.
        • Hellmann M.D.
        • Barron D.A.
        • Schram A.M.
        • Hameed M.
        • Dogan S.
        • Ross D.S.
        • Hechtman J.F.
        • DF DeLair
        • Yao J.
        • Mandelker D.L.
        • Cheng D.T.
        • Chandramohan R.
        • Mohanty A.S.
        • Ptashkin R.N.
        • Jayakumaran G.
        • Prasad M.
        • Syed M.H.
        • Rema A.B.
        • Liu Z.Y.
        • Nafa K.
        • Borsu L.
        • Sadowska J.
        • Casanova J.
        • Bacares R.
        • Kiecka I.J.
        • Razumova A.
        • Son J.B.
        • Stewart L.
        • Baldi T.
        • Mullaney K.A.
        • Al-Ahmadie H.
        • Vakiani E.
        • Abeshouse A.A.
        • Penson A.V.
        • Jonsson P.
        • Camacho N.
        • Chang M.T.
        • Won H.H.
        • Gross B.E.
        • Kundra R.
        • Heins Z.J.
        • Chen H.W.
        • Phillips S.
        • Zhang H.
        • Wang J.
        • Ochoa A.
        • Wills J.
        • Eubank M.
        • Thomas S.B.
        • Gardos S.M.
        • Reales D.N.
        • Galle J.
        • Durany R.
        • Cambria R.
        • Abida W.
        • Cercek A.
        • Feldman D.R.
        • Gounder M.M.
        • Hakimi A.A.
        • Harding J.J.
        • Iyer G.
        • Janjigian Y.Y.
        • Jordan E.J.
        • Kelly C.M.
        • Lowery M.A.
        • LGT Morris
        • Omuro A.M.
        • Raj N.
        • Razavi P.
        • Shoushtari A.N.
        • Shukla N.
        • Soumerai T.E.
        • Varghese A.M.
        • Yaeger R.
        • Coleman J.
        • Bochner B.
        • Riely G.J.
        • Saltz L.B.
        • Scher H.I.
        • Sabbatini P.J.
        • Robson M.E.
        • Klimstra D.S.
        • Taylor B.S.
        • Baselga J.
        • Schultz N.
        • Hyman D.M.
        • Arcila M.E.
        • Solit D.B.
        • Ladanyi M.
        • Berger M.F.
        Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
        Nat. Med. 2017; 23: 703-713
        • FDA
        FDA Grants Accelerated Approval to Pembrolizumab for First Tissue/Site Agnostic Indication.
        2017
        • KGaA M.
        Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer.
        2018
        • NIH
        Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100).
        2018
        • Ledermann J.
        • Harter P.
        • Gourley C.
        • Friedlander M.
        • Vergote I.
        • Rustin G.
        • Scott C.L.
        • Meier W.
        • Shapira-Frommer R.
        • Safra T.
        • Matei D.
        • Fielding A.
        • Spencer S.
        • Dougherty B.
        • Orr M.
        • Hodgson D.
        • Barrett J.C.
        • Matulonis U.
        Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
        Lancet Oncol. 2014; 15: 852-861
        • Aghajanian C.
        • Goff B.
        • Nycum L.R.
        • Wang Y.V.
        • Husain A.
        • Blank S.V.
        Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.
        Gynecol. Oncol. 2015; 139: 10-16
        • Mirza M.R.
        • Monk B.J.
        • Herrstedt J.
        • Oza A.M.
        • Mahner S.
        • Redondo A.
        • Fabbro M.
        • Ledermann J.A.
        • Lorusso D.
        • Vergote I.
        • Ben-Baruch N.E.
        • Marth C.
        • Madry R.
        • Christensen R.D.
        • Berek J.S.
        • Dorum A.
        • Tinker A.V.
        • du Bois A.
        • Gonzalez-Martin A.
        • Follana P.
        • Benigno B.
        • Rosenberg P.
        • Gilbert L.
        • Rimel B.J.
        • Buscema J.
        • Balser J.P.
        • Agarwal S.
        • Matulonis U.A.
        • Investigators E.-O.N.
        Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer.
        N. Engl. J. Med. 2016; 375: 2154-2164
        • Coleman R.L.
        • Brady M.F.
        • Herzog T.J.
        • Sabbatini P.
        • Armstrong D.K.
        • Walker J.L.
        • Kim B.G.
        • Fujiwara K.
        • Tewari K.S.
        • O'Malley D.M.
        • Davidson S.A.
        • Rubin S.C.
        • DiSilvestro P.
        • Basen-Engquist K.
        • Huang H.
        • Chan J.K.
        • Spirtos N.M.
        • Ashfaq R.
        • Mannel R.S.
        Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
        Lancet Oncol. 2017; 18: 779-791
        • Coleman R.L.
        • Oza A.M.
        • Lorusso D.
        • Aghajanian C.
        • Oaknin A.
        • Dean A.
        • Colombo N.
        • Weberpals J.I.
        • Clamp A.
        • Scambia G.
        • Leary A.
        • Holloway R.W.
        • Gancedo M.A.
        • Fong P.C.
        • Goh J.C.
        • O'Malley D.M.
        • Armstrong D.K.
        • Garcia-Donas J.
        • Swisher E.M.
        • Floquet A.
        • Konecny G.E.
        • IA McNeish
        • Scott C.L.
        • Cameron T.
        • Maloney L.
        • Isaacson J.
        • Goble S.
        • Grace C.
        • Harding T.C.
        • Raponi M.
        • Sun J.
        • Lin K.K.
        • Giordano H.
        • Ledermann J.A.
        • investigators A
        Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
        Lancet. 2017; 390: 1949-1961
        • Bindra R.S.
        • Crosby M.E.
        • Glazer P.M.
        Regulation of DNA repair in hypoxic cancer cells.
        Cancer Metastasis Rev. 2007; 26: 249-260
        • Liu J.F.
        • Barry W.T.
        • Birrer M.
        • Lee J.M.
        • Buckanovich R.J.
        • Fleming G.F.
        • Rimel B.
        • Buss M.K.
        • Nattam S.
        • Hurteau J.
        • Luo W.
        • Quy P.
        • Whalen C.
        • Obermayer L.
        • Lee H.
        • Winer E.P.
        • Kohn E.C.
        • Ivy S.P.
        • Matulonis U.A.
        Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
        Lancet Oncol. 2014; 15: 1207-1214
        • Mirza M.R.
        • Mortensen C.E.
        • Avall-lLundqvist E.
        • Bjorge L.
        • Berek J.S.
        • Herrstedt J.
        • Holm A.J.
        • Kirkegaraard T.
        • Maenpaa J.
        ENGOT-OV24-NSGO/AVANOVA: Niraparib versus bevacizumab-niraparib combination versus bevacizumab and niraparib as sequential therapy in women with platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.
        J. Clin. Oncol. 2015; 33 (abstr TPS5607)
        • Hannani D.
        • Sistigu A.
        • Kepp O.
        • Galluzzi L.
        • Kroemer G.
        • Zitvogel L.
        Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy.
        Cancer J. 2011; 17: 351-358
        • Galluzzi L.
        • Senovilla L.
        • Zitvogel L.
        • Kroemer G.
        The secret ally: immunostimulation by anticancer drugs.
        Nat. Rev. Drug Discov. 2012; 11: 215-233
        • Vanneman M.
        • Dranoff G.
        Combining immunotherapy and targeted therapies in cancer treatment.
        Nat. Rev. Cancer. 2012; 12: 237-251
        • Chen D.S.
        • Mellman I.
        Oncology meets immunology: the cancer-immunity cycle.
        Immunity. 2013; 39: 1-10
        • Jiao S.
        • Xia W.
        • Yamaguchi H.
        • Wei Y.
        • Chen M.K.
        • Hsu J.M.
        • Hsu J.L.
        • Yu W.H.
        • Du Y.
        • Lee H.H.
        • Li C.W.
        • Chou C.K.
        • Lim S.O.
        • Chang S.S.
        • Litton J.
        • Arun B.
        • Hortobagyi G.N.
        • Hung M.C.
        PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression.
        Clin. Cancer Res. 2017; 23: 3711-3720
        • Konstantinopoulos P.A.
        • Waggoner S.E.
        • Vidal G.A.
        • Mita M.M.
        • FLeming G.F.
        • Holloway R.W.
        • Van Le L.
        • Sachdev J.C.
        • C-D E.
        • Colon-Otero G.
        • Penson R.T.
        • Matulonis U.A.
        • KY B.
        • Moore K.N.
        • Swisher E.M.
        • D'ezube B.J.
        • Wang J.Y.
        • Buerstatte N.
        • Arora S.
        • Munster P.N.
        TOPACIO/Keynote-162 (NCT02657889): a phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC) - results from ROC cohort.
        J. Clin. Oncol. 2018; (absr 106)
        • Ray-Coquard I.
        • Selle F.
        • Harter P.
        • Cropet C.
        • Marth C.
        • Vergote I.
        • Fujiwara K.
        • Gonzalez Martin A.
        • Pujade-Lauraine E.
        PAOLA-1: An ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab.
        J. Clin. Oncol. 2016; 34 (abstr TPS5607)
        • ENGOT
        Ovarian Cancer Clinical Trials (as of April 2018).
        2018
        • NIH
        A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA).
        2018
        • NIH
        Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100).
        2018
        • NIH
        Study of Niraparib or Carboplatin-Paclitaxel in Combination With TSR-042 or With TSR-042 and Bevacizumab.
        2017
        • NIH
        Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients.
        (DUO-O)2018
        • NIH
        Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/ENGOT-ov43).
        2018
        • Walker J.
        • Brady M.F.
        • DiSilvestro P.A.
        • Fujiwara K.
        • Alberts D.
        • Zheng W.
        • Tewari K.
        • Cohn D.E.
        • Powell M.
        • Van Le L.
        • Rubin S.
        • Davidson S.A.
        • Gray H.J.
        • Waggoner S.
        • Myers T.
        • Aghajanian C.
        • Secord A.A.
        • Mannel R.S.
        A phase III trial of bevacizumab with IV versus IP chemotherapy for ovarian, fallopian tube, and peritoneal carcinoma: an NRG Oncology Study.
        Gynecol. Oncol. 2016; 141: 208
        • Lesnock J.L.
        • Darcy K.M.
        • Tian C.
        • Deloia J.A.
        • Thrall M.M.
        • Zahn C.
        • Armstrong D.K.
        • Birrer M.J.
        • Krivak T.C.
        BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.
        Br. J. Cancer. 2013; 108: 1231-1237
        • Naumann R.W.
        • Morris J.C.
        • Tait D.L.
        • Higgins R.V.
        • Crane E.K.
        • Drury L.K.
        • Amacker-North L.
        • Templin M.
        • Brown J.
        Patients with BRCA mutations have superior outcomes after intraperitoneal chemotherapy in optimally resected high grade ovarian cancer.
        Gynecol. Oncol. 2018; 151: 477-480https://doi.org/10.1016/j.ygyno.2018.10.003
        • van Driel W.J.
        • Koole S.N.
        • Sikorska K.
        • Schagen van Leeuwen J.H.
        • Schreuder H.W.R.
        • Hermans R.H.M.
        • de Hingh I.
        • van der Velden J.
        • Arts H.J.
        • Massuger L.
        • Aalbers A.G.J.
        • Verwaal V.J.
        • Kieffer J.M.
        • Van de Vijver K.K.
        • van Tinteren H.
        • Aaronson N.K.
        • Sonke G.S.
        Hyperthermic intraperitoneal chemotherapy in ovarian cancer.
        N. Engl. J. Med. 2018; 378: 230-240
        • Pignata S.
        • Lorusso D.
        • Joly C.
        • Gallo C.
        • Colombo N.
        • Sessa C.
        • Bamia A.
        • Pisano C.
        • Selle F.
        • Zaccarelli E.
        • Scambia G.
        • Pautier P.
        • Nicoletto M.O.
        • De Giorgi U.
        • Dubot C.
        • Bologna A.
        • Orditura M.
        • Ray-Coquard I.
        • Perrone F.
        • Daniele G.
        Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: the randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17.
        J. Clin. Oncol. 2018; 36

      Linked Article